Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

(2016) Kefang Liu et al.   CELL RESEARCH

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab

(2016) Zhenkun Na et al.   CELL RESEARCH

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway

(2016) Mei-Miao Zhan et al.   DRUG DISCOVERY TODAY

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

(2016) Frank A. Schildberg et al.   IMMUNITY

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

(2016) Baihao Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy

(2015) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

(2015) Roy L. Maute et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy

(2014) W.-S. Chang et al.   JOURNAL OF IMMUNOLOGY

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

(2013) Xiaoxiao Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L2 is predominantly expressed by Th2 cells

(2011) W. Joost Lesterhuis et al.   MOLECULAR IMMUNOLOGY

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

A dimeric structure of PD-L1: functional units or evolutionary relics?

(2010) Yong Chen et al.   Protein & Cell

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells

(2008) Yu Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

(2008) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA